IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Inclusion criteria

• Have a diagnosis of plaque-type psoriasis for at least 6 months;
• Psoriasis Area and Severity Index (PASI) score of 12 or greater, AND static Physician's Global Assessment (sPGA) score of 3 (moderate) or greater; Psoriasis covering at least 10% of body surface area;
• Must be a candidate for either systemic therapy or phototherapy for psoriasis.

Exclusion criteria

• Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (for example, compromise the well-being) of the participant or that could prevent, limit, or confound the protocol-specified assessments
• Participants who have ever received IBI112 or IL-23 inhibitor
• History or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
• Has any condition that, in the opinion of the investigator, would make participation not be in the best interest of the participant
• Is pregnant, nursing, or planning a pregnancy (both men and women) within 6 months following the last administration of the study drug